Research Notice: This article covers the pre-mixed CJC-1295 No DAC / Ipamorelin Blend research compound — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: This product is sold exclusively for in vitro and legitimate laboratory research purposes. It is not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

CJC-1295/Ipamorelin Blend: Complete Research & Buying Guide

Last Updated: August 2, 2026 | Reading Time: Approximately 12 minutes | Author: Palmetto Peptides Research Team

---

Quick Answer

The CJC-1295 No DAC / Ipamorelin Blend is a co-lyophilized research compound that combines both peptides into a single vial at a fixed 1:1 ratio, sold in 5mg/5mg and 10mg/10mg variants. It exists because CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor/GHS-R1a) are the most frequently paired GH secretagogues in preclinical research, and co-lyophilizing them eliminates the need to weigh, reconstitute, and combine two separate vials by hand for every administration. The trade-off is fixed-ratio dosing — if a protocol requires an off-1:1 ratio or the DAC variant of CJC-1295, the two compounds should be purchased and reconstituted separately instead.

---

Table of Contents

1. What the Blend Actually Is
2. Why a Pre-Mixed, Co-Lyophilized Format
3. Dosing the Blend: Reading the 5/5mg and 10/10mg Labels
4. Reconstitution Basics for the Co-Lyophilized Vial
5. Blend vs. Buying Separately: The Decision Framework
6. Storage and Stability
7. Quality and Third-Party Testing
8. Frequently Asked Questions

---

What the Blend Actually Is

The CJC-1295 No DAC / Ipamorelin Blend is not two separate compounds packaged together — it is a single vial in which both peptides are dissolved and freeze-dried (lyophilized) together, a process called co-lyophilization. The result is one lyophilized cake containing a fixed ratio of CJC-1295 No DAC (Mod GRF 1-29, molecular weight approximately 3,367.9 Da) and Ipamorelin (molecular weight approximately 711.9 Da).

Palmetto Peptides sells the blend in two dose variants:

• 5mg/5mg — 5mg CJC-1295 No DAC and 5mg Ipamorelin co-lyophilized in one vial
• 10mg/10mg — 10mg CJC-1295 No DAC and 10mg Ipamorelin co-lyophilized in one vial

Both variants use CJC-1295 without DAC (Mod GRF 1-29), not the DAC variant. This is deliberate — see the mechanism discussion below.

For the full mechanistic literature review on why these two compounds are paired in the first place, see our CJC-1295 + Ipamorelin Research Stack 2026 guide, which covers the GHRH/ghrelin dual-receptor synergy in depth. This article focuses specifically on the pre-mixed blend product itself: what it is, how to dose and reconstitute it, and when it makes sense versus buying the two peptides separately.

---

Why a Pre-Mixed, Co-Lyophilized Format

CJC-1295 and Ipamorelin are already two of the most frequently co-administered compounds in GH secretagogue research, precisely because they act on independent receptor pathways (GHRH receptor for CJC-1295, GHS-R1a for Ipamorelin) that converge on GH secretion through different intracellular cascades. Researchers running protocols that call for both compounds at a fixed ratio, on the same schedule, for every administration, have three practical options:

1. Purchase and reconstitute two separate vials, then manually combine calculated volumes for every dose
2. Purchase and reconstitute two separate vials, then draw and inject them separately at each session
3. Purchase the co-lyophilized blend, which requires only one reconstitution and one draw per administration

The co-lyophilized format exists to serve the third option. Because both peptides are freeze-dried together in a single, precisely weighed batch, the ratio between them is fixed by manufacturing rather than by hand-measurement at the bench, which removes one source of pipetting or weighing error from a multi-vial protocol.

---

Dosing the Blend: Reading the 5/5mg and 10/10mg Labels

The variant naming convention (5mg/5mg, 10mg/10mg) refers to the total mass of each individual peptide in the vial, not a combined total. A 5mg/5mg vial contains 5mg of CJC-1295 No DAC and 5mg of Ipamorelin — 10mg of total peptide mass, at a 1:1 ratio by weight between the two compounds.

Variant	CJC-1295 No DAC	Ipamorelin	Total Peptide Mass	Ratio
5mg/5mg	5mg	5mg	10mg	1:1
10mg/10mg	10mg	10mg	20mg	1:1

Because the ratio is fixed at 1:1 by weight, researchers whose protocol calls for a different ratio between the two compounds (for example, a study specifically isolating dose-response asymmetries) should purchase CJC-1295 No DAC and Ipamorelin as separate products and reconstitute them independently, allowing full control over the ratio delivered.

---

Reconstitution Basics for the Co-Lyophilized Vial

Reconstituting the blend follows the same general principles as reconstituting any lyophilized research peptide, with one important difference from a two-vial protocol: only one reconstitution step is needed per administration cycle, since both compounds already share a vial.

1. Confirm the labeled fill weight on the COA before calculating target concentration — do not assume the nominal label amount matches the exact measured fill.
2. Use bacteriostatic water (0.9% benzyl alcohol) as the reconstitution vehicle for extended stability across repeated draws.
3. Direct the water against the glass wall of the vial, not directly onto the lyophilized cake, to avoid foaming or denaturation.
4. Swirl gently to dissolve — do not shake or vortex.
5. Inspect visually. A properly reconstituted co-lyophilized blend should be clear and colorless with no particulate matter.

Example concentration math for the 5mg/5mg vial: adding 2mL of bacteriostatic water yields a solution containing 2.5mg/mL of CJC-1295 No DAC and 2.5mg/mL of Ipamorelin simultaneously (since both compounds dissolve together in the same total volume). A researcher targeting a combined 100mcg/100mcg dose per administration would draw 0.04mL (4 units on a standard insulin syringe) from that reconstituted vial.

For step-by-step reconstitution protocols covering the individual peptides in more technical detail, see our CJC-1295 Reconstitution Guide and Ipamorelin Reconstitution Guide, or use the CJC-1295 Reconstitution Calculator and Ipamorelin Reconstitution Calculator for single-compound dosing tables.

---

Blend vs. Buying Separately: The Decision Framework

Research Need	Best Option	Reasoning
Standard 1:1 ratio, single reconstitution per session	Co-lyophilized blend	One vial, one reconstitution, ratio fixed by manufacturing
Non-1:1 or study-specific ratio	Separate vials	Full control over the ratio delivered per administration
CJC-1295 with DAC pairing (sustained-release protocols)	Separate vials	Blend only ships with the No DAC variant
Staggered or offset-timing administration of each compound	Separate vials	Blend delivers both compounds simultaneously in one draw
Minimizing bench time and pipetting steps across a multi-week protocol	Co-lyophilized blend	Fewer reconstitution and combination steps per cycle

Cost is a secondary factor worth noting: the 5mg/5mg blend is priced at $84 and the 10mg/10mg blend at $144, comparable to purchasing 5mg or 10mg of each compound separately, so the blend format is priced for convenience rather than at a premium or discount relative to buying both peptides individually.

---

Storage and Stability

Storage guidance for the co-lyophilized blend mirrors standard lyophilized peptide handling, with the DAC-specific thiol-buffer restriction not applicable since the blend uses the No DAC variant:

• Store the lyophilized vial at -20°C or below, protected from light
• Allow the vial to reach room temperature before opening to prevent condensation
• Once reconstituted, store at 2 to 8°C and use within 14 to 28 days
• Avoid repeated freeze-thaw cycles of the reconstituted solution
• Discard if the solution shows cloudiness, particulates, or discoloration

---

Quality and Third-Party Testing

Every batch of the CJC-1295 No DAC / Ipamorelin Blend is co-lyophilized and tested as a single lot, with a batch-specific Certificate of Analysis confirming purity (≥98% HPLC for both compounds) and identity via mass spectrometry. Testing is performed by an independent, ISO-accredited third-party laboratory in the United States, and the product is manufactured domestically.

Product link: View the CJC-1295 No DAC / Ipamorelin Blend — 5mg/5mg and 10mg/10mg variants, with lot-specific COA documentation available on the product page.

---

Common Use Cases in Preclinical Protocols

The blend format is best suited to research protocols where the two-compound ratio is decided once, at the design stage, and then held constant across the entire study. In practice, this covers a large share of published GH secretagogue research designs, since most preclinical models pairing a GHRH-receptor agonist with a ghrelin-receptor agonist use a matched or near-matched dose of each compound rather than a heavily skewed ratio. Typical scenarios where researchers reach for a co-lyophilized format instead of two separate vials include:

• Multi-week or multi-month protocols where reducing the number of reconstitution and combination steps at each administration meaningfully cuts total bench time across the study
• Studies replicating a previously published 1:1 CJC-1295/Ipamorelin protocol, where the ratio has already been validated in the literature and does not need to be varied
• Facilities running multiple concurrent protocols, where fewer vials in circulation simplifies inventory tracking, labeling, and cold-chain storage logistics

Conversely, dose-ranging studies, studies isolating the independent contribution of each receptor pathway, or protocols adapted from designs using CJC-1295 with DAC are generally better served by the separate-vial approach described in the decision framework above and covered in more depth in our Blend vs. Buying Separately comparison.

---

Frequently Asked Questions

Is the CJC-1295/Ipamorelin blend the same as buying both peptides separately and mixing them myself?

Functionally similar in terms of the compounds delivered, but not identical in process. The blend is co-lyophilized at the manufacturing stage, meaning the 1:1 ratio is fixed before the vial reaches the lab. Mixing two separately reconstituted vials by hand introduces additional measurement steps and gives the researcher full control over ratio and timing, at the cost of extra bench work per administration.

Why does the blend only use CJC-1295 No DAC and not the DAC variant?

CJC-1295 No DAC (Mod GRF 1-29) produces pulsatile GH release with a short half-life, more closely matching the timing of a single Ipamorelin administration. Pairing it with Ipamorelin in one co-administered dose keeps both compounds acting within a similar time window. CJC-1295 with DAC has a multi-day half-life, which does not pair naturally with a single-session co-lyophilized product.

Can I get a custom ratio other than 1:1?

Not in the pre-mixed blend format — the 1:1 ratio is fixed by the co-lyophilization process. Researchers who need a different ratio should purchase CJC-1295 No DAC and Ipamorelin separately and reconstitute each to the desired concentration.

How many total peptide milligrams are in each vial?

The 5mg/5mg vial contains 10mg of total peptide mass (5mg CJC-1295 No DAC plus 5mg Ipamorelin). The 10mg/10mg vial contains 20mg total (10mg plus 10mg).

Is this product approved for human use?

No. The CJC-1295 No DAC / Ipamorelin Blend is sold exclusively for licensed laboratory and in vitro research. It is not approved by the FDA or any regulatory authority for human consumption, veterinary use, or any clinical application.

Does buying the blend save reconstitution time compared to two vials?

Yes, in terms of hands-on bench steps. A two-vial protocol requires two independent reconstitution calculations, two swirl/dissolve steps, and either a combined or dual draw at each administration. The blend collapses this to a single reconstitution and a single draw, which becomes a more meaningful time saving the longer a protocol runs and the more administrations it involves.

Will the concentration of each compound always match between the two peptides after reconstitution?

Yes, as long as the vial is reconstituted according to label instructions. Because the blend is manufactured with equal masses of CJC-1295 No DAC and Ipamorelin, any volume of bacteriostatic water added produces identical mg/mL concentrations of both compounds — see our Reconstitution & Dosing Guide for the full concentration tables across both vial sizes.

---

Related Research

• CJC-1295 + Ipamorelin Research Stack 2026: Synergistic GH Release Mechanism
• CJC-1295/Ipamorelin Blend Reconstitution & Dosing Guide
• Pre-Mixed Blend vs. Buying Separately: What Research Buyers Should Know
• Complete CJC-1295 Research Guide
• Complete Ipamorelin Research Guide
• Best GH Secretagogue Research Stacks 2026

---

Peer-Reviewed Citations

1. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
2. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
3. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting growth hormone-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.
4. Frohman LA, Jansson JO. "Growth hormone-releasing hormone." Endocrine Reviews. 1986;7(3):223-253.

---

This article was written and reviewed by the Palmetto Peptides Research Team.

All products referenced are sold for research purposes only. Nothing in this article constitutes medical advice or a recommendation for human use.